Email: cspc@cspc.cn
Media
News Center
Jul. 02
2026
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL STUDY OF SYH2095 TABLETS AS A MONOTHERAPY OR IN COMBINATION REGIMENS FOR THE TREATMENT OF ADVANCED MALIGNANT TUMOURS O
VOLUNTARY ANNOUNCEMENT - RECOMBINANT HERPES ZOSTER VACCINE (SYS6052) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
VOLUNTARY ANNOUNCEMENT - IRON SUCROSE INJECTION RECEIVES MARKETING APPROVAL
VOLUNTARY ANNOUNCEMENT - SYS6043 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER, PRIMARY PERITONEAL CA
Jun. 30
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE ADJUVANT TREATMENT OF RESECTED STAGE II-IIIB NON-SMALL CEL
Jun. 26
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE TREATMENT OF DRIVER GENE-NEGATIVE NON-SMALL CELL LUNG CANC
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
